QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:TRIB

Trinity Biotech - TRIB Stock Forecast, Price & News

$1.40
+0.02 (+1.45%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.35
$1.42
50-Day Range
$1.21
$1.41
52-Week Range
$0.86
$3.05
Volume
17,423 shs
Average Volume
324,260 shs
Market Capitalization
$37.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TRIB stock logo

About Trinity Biotech (NASDAQ:TRIB) Stock

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TRIB shares. StockNews.com started coverage on shares of Trinity Biotech in a research note on Tuesday, August 9th. They issued a "buy" rating on the stock. TheStreet lowered shares of Trinity Biotech from a "c-" rating to a "d" rating in a research note on Tuesday, July 5th.

Trinity Biotech Stock Down 2.1 %

Shares of NASDAQ:TRIB traded down $0.03 during mid-day trading on Tuesday, hitting $1.38. The company's stock had a trading volume of 17,996 shares, compared to its average volume of 39,646. Trinity Biotech has a one year low of $0.86 and a one year high of $3.05. The company's fifty day simple moving average is $1.33 and its 200-day simple moving average is $1.21.

Trinity Biotech (NASDAQ:TRIB - Get Rating) last released its quarterly earnings data on Thursday, June 30th. The company reported ($0.08) earnings per share for the quarter. Trinity Biotech had a negative return on equity of 347.92% and a negative net margin of 15.10%. The firm had revenue of $18.78 million for the quarter.

Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Stock News Headlines

Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update
Trinity Biotech reports Q4 results
Trinity Biotech wins WHO approval for HIV screening test
See More Headlines
Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Company Calendar

Last Earnings
6/30/2022
Today
8/16/2022
Next Earnings (Estimated)
9/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRIB
Employees
543
Year Founded
1992

Profitability

Net Income
$880,000.00
Pretax Margin
-3.70%

Debt

Sales & Book Value

Annual Sales
$92.96 million
Cash Flow
$0.56 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
24,711,000
Market Cap
$37.69 million
Optionable
Optionable
Beta
1.33

Social Links


Key Executives

  • Mr. Ronan O'Caoimh (Age 66)
    Chief Exec. Officer
    Comp: $643k
  • Mr. John Gillard (Age 41)
    CFO, Company Sec. & Exec. Director
    Comp: $593k
  • Dr. James Walsh Ph.D. (Age 64)
    Exec. Director
    Comp: $20k
  • Mr. Simon Dunne (Age 48)
    Chief Accounting Officer
  • Ms. Eibhlin Kelly (Age 38)
    Chief Information Officer
  • Mr. Fernando Devia (Age 59)
    Exec. VP of Sales
  • Mr. Sanjiv Suri (Age 63)
    Sr. VP of Global Sales & GM of North America













TRIB Stock - Frequently Asked Questions

How have TRIB shares performed in 2022?

Trinity Biotech's stock was trading at $1.43 at the start of the year. Since then, TRIB shares have decreased by 2.1% and is now trading at $1.40.
View the best growth stocks for 2022 here
.

When is Trinity Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 8th 2022.
View our TRIB earnings forecast
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) issued its quarterly earnings data on Thursday, June, 30th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm earned $18.78 million during the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative trailing twelve-month return on equity of 347.92%.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hunter Associates Investment Management LLC (6.72%), Renaissance Technologies LLC (5.58%) and LPL Financial LLC (0.18%).

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $1.40.

How much money does Trinity Biotech make?

Trinity Biotech (NASDAQ:TRIB) has a market capitalization of $37.69 million and generates $92.96 million in revenue each year. The company earns $880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Trinity Biotech have?

The company employs 543 workers across the globe.

When was Trinity Biotech founded?

Trinity Biotech was founded in 1992.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The official website for the company is www.trinitybiotech.com. The company can be reached via phone at (531) 276-9800, via email at kevin.tansley@trinitybiotech.com, or via fax at 353-1276-9888.

This page (NASDAQ:TRIB) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.